About the Global Campaign

In countries from the U.S. to Vietnam, Brazil to Indonesia, health groups are aiming to break Abbott’s monopoly control over lopinavir+ritonavir (Kaletra). Campaigners say Abbott’s high price for Kaletra is blocking expansion of AIDS treatment, and its anti-competitive practices are impeding new drug innovation.

Kaletra campaign flyer

Press Release (November 9, 2011)

English | Español | Chinese

Access Story Spotlight

"I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need." --Naza of Malaysia's PT Foundation


Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK

Read about how Abbott is seeking to artificially extend its patents on lopinavir+ritonavir

Read full article here


Information About Ritonavir (Kaletra Component)

English | Español


Campaign Actions FAQ (Compulsory Licensing, Patent Opposition, March-In Request, Voluntary Licensing)

English | Español

 

TRIPS & Public Health FAQ - World Trade Organization

English | Español

 

 

 

 

Atazanavir Campaign News


 

Atazanavir in the News


 

Kaletra Campaign News


 

 

Return to the Kaletra Campaign Homepage